High complexity and limited pipeline coverage for many upcoming biologic patent expiries create a biosimilar “void” that manufacturers must address https://www.einpresswire.com/article/833505102/biosimilars-and-biologics-market-growth-driven-by-patent-expiries-innovation-datam-intelligence